Novo Nordisk A/S (WSE:NVO)
Poland · Delayed Price · Currency is PLN | Market Cap | 818.27B -27.0% |
| Revenue (ttm) | 188.41B +8.1% |
| Net Income | 70.10B +16.6% |
| EPS | 15.75 +16.8% |
| Shares Out | n/a |
| PE Ratio | 11.67 |
| Forward PE | 16.00 |
| Dividend | 6.69 (3.61%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 32 |
| Open | 188.26 |
| Previous Close | 181.74 |
| Day's Range | 188.26 - 188.26 |
| 52-Week Range | 129.26 - 263.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
Eli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy. Lilly has been winning the race to dominate the GLP-1 drug market.
Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements
The two companies dominate the market for obesity medications.
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk (NVO) Seeks Court Order Against Eli Lilly (LLY) Over Misleading Ads
Novo Nordisk (NVO) Seeks Court Order Against Eli Lilly (LLY) Over Misleading Ads
Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads
Denmark's Novo Nordisk said on Tuesday that it had sued Lilly, arguing consumers were being misled about how the companies' products compare.
Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads
Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry bet...
BMO's Evan Seigerman: I prefer Eli Lilly over Novo Nordisk in the obesity trade
BMO's Evan Seigerman joins 'Power Lunch' to talk about what he is looking for when it comes to the upcoming slate of healthcare earnings.
Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications
MCLEAN, Va.--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healt...
Weight loss drugs linked to increase risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
Hair loss with GLP-1 drugs is rare, but real, studies find
The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
Many US patients opt for obesity drug injections, defying some expectations
Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health insurance program for Americans aged 65 ...
Novo Nordisk sues Eli Lilly in US over ‘misleading’ obesity drug advertising claims
Market Today: Novo Nordisk Sues Eli Lilly; GM Profits Surge; AMD, Nebius Jump
Market Today: Novo Nordisk Sues Eli Lilly; GM Profits Surge; AMD, Nebius Jump
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.
Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the high...
Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing
The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.
Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective Ozempic maker Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “fal...
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.
Novo Nordisk (NVO) Sues Eli Lilly Over Misleading Drug Advertising
Novo Nordisk (NVO) Sues Eli Lilly Over Misleading Drug Advertising
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo'...
Eli Lilly (LLY) Hit with Lawsuit by Rival Novo Nordisk Over Weight-Loss Drug Ads
Competition between the drug makers is intensifying.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ...
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing
Novo Nordisk is one of the leading makers of GLP-1 weight-loss drugs. The stock has a well-above-market yield that is also well above its industry peers.